The Biotech Investor's Playbook: How to Evaluate Clinical-Stage Companies

Why Biotech Is Different

Biotech investing is unlike any other sector. Companies can double or get cut in half overnight based on a single data readout. There's no revenue to analyze, no P/E ratio to compare. It's all about science, probability, and timing.

But here's the thing: if you build the right framework, biotech offers the highest risk-adjusted returns of any sector. You just need to know what to look for.

The Four Pillars of Biotech Analysis

1. The Science

You don't need a PhD, but you need to understand the mechanism of action. What does the drug do? Why might it work? What's the biological rationale?

Resources: PubMed for research papers, company investor presentations for plain-English explanations, ClinicalTrials.gov for trial designs.

2. The Market Opportunity

A drug that works for a disease affecting 10,000 people globally has a very different commercial potential than one targeting 10 million. Look for large TAM (total addressable market), limited competition, and clear unmet medical need.

3. The Data

Clinical trial data is everything. Key metrics to evaluate: p-value (statistical significance), effect size (how much does it help?), safety profile (side effects), and comparison to existing treatments.

4. The Catalyst Timeline

Map out every upcoming catalyst: data readouts, FDA advisory committee meetings, PDUFA dates, conference presentations. This is your trading calendar.

Position Sizing for Binary Events

My rule: never more than 3% of portfolio in any single biotech before a binary catalyst. Split into 1.5% before and add 1.5% after a positive readout if the setup still works.

The math is simple: if you have 10 biotech positions at 3% each, a complete wipeout on one costs you 3% of your portfolio. Painful but survivable. A 100% gain on another one covers it plus some.